SU‐GG‐J‐153: Voxel‐Based Phenomenological SUV‐Dose Response Model for the Human Parotid Glands

B. Cannon, S. Tucker, M. Chambers, A. Garden, M. Martel, D. Schwartz, L. Dong

Research output: Contribution to journalArticle

Abstract

Purpose: The goal of this study is to evaluate SUV as an imaging biomarker of parotid function following radiotherapy (RT) and to develop a phenomenological model of SUV‐dose response, enabling prediction of the biomarker prior to RT. Method and Materials: As part of an ongoing study, patients (n = 8) with head and neck cancer (HNC) had 18F‐FDG PET/CT studies performed before (within 30 days) and following RT (∼50 days). In addition, resting and stimulated whole mouth saliva was collected. Next, a deformable image registration algorithm was utilized to map parotid contours from planning CT (PCT) images to pre‐ and post‐RT PET/CT studies, separately. Mean SUV was then calculated for the parotid glands at both time points and compared to collected saliva. The SUV‐dose response relationship was assessed in a separate cohort (n = 60) also treated for HNC. Pre‐ and post‐RT PET/CT images were deformably aligned to PCT images to achieve correspondence between SUV and planned dose. SUV response was then modeled using a single parameter, incorporating planned dose and pre‐RT SUV; defined as metabolic dose. Results: Post‐RT stimulated saliva and SUV decreased (59% and 20%, respectively) in seven patients. For one patient, stimulated saliva and SUV increased (14% and 11%, respectively). Fractional SUV correlated significantly with xerostomia grade, P < 0.01 and Spearman's ρ = −0.964. A second order polynomial provided an adequate fit to the log transformed SUV‐dose response curve, adjusted R2 = 0.95. Post‐RT SUV was predicted within 3% for an exemplary patient, but overestimated (50%) in the worst case. Conclusions: Pilot data suggest that SUV is significantly correlated with parotid saliva output. Furthermore, the feasibility of predicting reductions in SUV, prior to treatment delivery, has been demonstrated. Conflict of Interest: Research partially sponsored by Varian Medical Systems.

Original languageEnglish (US)
Number of pages1
JournalMedical Physics
Volume37
Issue number6
DOIs
StatePublished - Jan 1 2010

Fingerprint

Parotid Gland
Saliva
Radiotherapy
Head and Neck Neoplasms
Biomarkers
Xerostomia
Conflict of Interest
Mouth
Research

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

SU‐GG‐J‐153 : Voxel‐Based Phenomenological SUV‐Dose Response Model for the Human Parotid Glands. / Cannon, B.; Tucker, S.; Chambers, M.; Garden, A.; Martel, M.; Schwartz, D.; Dong, L.

In: Medical Physics, Vol. 37, No. 6, 01.01.2010.

Research output: Contribution to journalArticle

Cannon, B. ; Tucker, S. ; Chambers, M. ; Garden, A. ; Martel, M. ; Schwartz, D. ; Dong, L. / SU‐GG‐J‐153 : Voxel‐Based Phenomenological SUV‐Dose Response Model for the Human Parotid Glands. In: Medical Physics. 2010 ; Vol. 37, No. 6.
@article{c9af2c50b80642d7b22970898816981d,
title = "SU‐GG‐J‐153: Voxel‐Based Phenomenological SUV‐Dose Response Model for the Human Parotid Glands",
abstract = "Purpose: The goal of this study is to evaluate SUV as an imaging biomarker of parotid function following radiotherapy (RT) and to develop a phenomenological model of SUV‐dose response, enabling prediction of the biomarker prior to RT. Method and Materials: As part of an ongoing study, patients (n = 8) with head and neck cancer (HNC) had 18F‐FDG PET/CT studies performed before (within 30 days) and following RT (∼50 days). In addition, resting and stimulated whole mouth saliva was collected. Next, a deformable image registration algorithm was utilized to map parotid contours from planning CT (PCT) images to pre‐ and post‐RT PET/CT studies, separately. Mean SUV was then calculated for the parotid glands at both time points and compared to collected saliva. The SUV‐dose response relationship was assessed in a separate cohort (n = 60) also treated for HNC. Pre‐ and post‐RT PET/CT images were deformably aligned to PCT images to achieve correspondence between SUV and planned dose. SUV response was then modeled using a single parameter, incorporating planned dose and pre‐RT SUV; defined as metabolic dose. Results: Post‐RT stimulated saliva and SUV decreased (59{\%} and 20{\%}, respectively) in seven patients. For one patient, stimulated saliva and SUV increased (14{\%} and 11{\%}, respectively). Fractional SUV correlated significantly with xerostomia grade, P < 0.01 and Spearman's ρ = −0.964. A second order polynomial provided an adequate fit to the log transformed SUV‐dose response curve, adjusted R2 = 0.95. Post‐RT SUV was predicted within 3{\%} for an exemplary patient, but overestimated (50{\%}) in the worst case. Conclusions: Pilot data suggest that SUV is significantly correlated with parotid saliva output. Furthermore, the feasibility of predicting reductions in SUV, prior to treatment delivery, has been demonstrated. Conflict of Interest: Research partially sponsored by Varian Medical Systems.",
author = "B. Cannon and S. Tucker and M. Chambers and A. Garden and M. Martel and D. Schwartz and L. Dong",
year = "2010",
month = "1",
day = "1",
doi = "10.1118/1.3468377",
language = "English (US)",
volume = "37",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "AAPM - American Association of Physicists in Medicine",
number = "6",

}

TY - JOUR

T1 - SU‐GG‐J‐153

T2 - Voxel‐Based Phenomenological SUV‐Dose Response Model for the Human Parotid Glands

AU - Cannon, B.

AU - Tucker, S.

AU - Chambers, M.

AU - Garden, A.

AU - Martel, M.

AU - Schwartz, D.

AU - Dong, L.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Purpose: The goal of this study is to evaluate SUV as an imaging biomarker of parotid function following radiotherapy (RT) and to develop a phenomenological model of SUV‐dose response, enabling prediction of the biomarker prior to RT. Method and Materials: As part of an ongoing study, patients (n = 8) with head and neck cancer (HNC) had 18F‐FDG PET/CT studies performed before (within 30 days) and following RT (∼50 days). In addition, resting and stimulated whole mouth saliva was collected. Next, a deformable image registration algorithm was utilized to map parotid contours from planning CT (PCT) images to pre‐ and post‐RT PET/CT studies, separately. Mean SUV was then calculated for the parotid glands at both time points and compared to collected saliva. The SUV‐dose response relationship was assessed in a separate cohort (n = 60) also treated for HNC. Pre‐ and post‐RT PET/CT images were deformably aligned to PCT images to achieve correspondence between SUV and planned dose. SUV response was then modeled using a single parameter, incorporating planned dose and pre‐RT SUV; defined as metabolic dose. Results: Post‐RT stimulated saliva and SUV decreased (59% and 20%, respectively) in seven patients. For one patient, stimulated saliva and SUV increased (14% and 11%, respectively). Fractional SUV correlated significantly with xerostomia grade, P < 0.01 and Spearman's ρ = −0.964. A second order polynomial provided an adequate fit to the log transformed SUV‐dose response curve, adjusted R2 = 0.95. Post‐RT SUV was predicted within 3% for an exemplary patient, but overestimated (50%) in the worst case. Conclusions: Pilot data suggest that SUV is significantly correlated with parotid saliva output. Furthermore, the feasibility of predicting reductions in SUV, prior to treatment delivery, has been demonstrated. Conflict of Interest: Research partially sponsored by Varian Medical Systems.

AB - Purpose: The goal of this study is to evaluate SUV as an imaging biomarker of parotid function following radiotherapy (RT) and to develop a phenomenological model of SUV‐dose response, enabling prediction of the biomarker prior to RT. Method and Materials: As part of an ongoing study, patients (n = 8) with head and neck cancer (HNC) had 18F‐FDG PET/CT studies performed before (within 30 days) and following RT (∼50 days). In addition, resting and stimulated whole mouth saliva was collected. Next, a deformable image registration algorithm was utilized to map parotid contours from planning CT (PCT) images to pre‐ and post‐RT PET/CT studies, separately. Mean SUV was then calculated for the parotid glands at both time points and compared to collected saliva. The SUV‐dose response relationship was assessed in a separate cohort (n = 60) also treated for HNC. Pre‐ and post‐RT PET/CT images were deformably aligned to PCT images to achieve correspondence between SUV and planned dose. SUV response was then modeled using a single parameter, incorporating planned dose and pre‐RT SUV; defined as metabolic dose. Results: Post‐RT stimulated saliva and SUV decreased (59% and 20%, respectively) in seven patients. For one patient, stimulated saliva and SUV increased (14% and 11%, respectively). Fractional SUV correlated significantly with xerostomia grade, P < 0.01 and Spearman's ρ = −0.964. A second order polynomial provided an adequate fit to the log transformed SUV‐dose response curve, adjusted R2 = 0.95. Post‐RT SUV was predicted within 3% for an exemplary patient, but overestimated (50%) in the worst case. Conclusions: Pilot data suggest that SUV is significantly correlated with parotid saliva output. Furthermore, the feasibility of predicting reductions in SUV, prior to treatment delivery, has been demonstrated. Conflict of Interest: Research partially sponsored by Varian Medical Systems.

UR - http://www.scopus.com/inward/record.url?scp=85024799675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024799675&partnerID=8YFLogxK

U2 - 10.1118/1.3468377

DO - 10.1118/1.3468377

M3 - Article

AN - SCOPUS:85024799675

VL - 37

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 6

ER -